Hurdle or thruster : Glucose metabolism of T cells in anti-tumour immunity
Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved..
Glucose metabolism is essential for the activation, differentiation and function of T cells and proper glucose metabolism is required to maintain effective T cell immunity. Dysregulation of glucose metabolism is a hallmark of cancer, and the tumour microenvironment (TME2) can create metabolic barriers in T cells that inhibit their anti-tumour immune function. Targeting glucose metabolism is a promising approach to improve the capacity of T cells in the TME. The efficacy of common immunotherapies, such as immune checkpoint inhibitors (ICIs3) and adoptive cell transfer (ACT4), can be limited by T-cell function, and the treatment itself can affect T-cell metabolism. Therefore, understanding the relationship between immunotherapy and T cell glucose metabolism helps to achieve more effective anti-tumour therapy. In this review, we provide an overview of T cell glucose metabolism and how T cell metabolic reprogramming in the TME regulates anti-tumour responses, briefly describe the metabolic patterns of T cells during ICI and ACT therapies, which suggest possible synergistic strategies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:1879 |
|---|---|
| Enthalten in: |
Biochimica et biophysica acta. Reviews on cancer - 1879(2024), 1 vom: 01. Jan., Seite 189022 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhang, Sirui [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adoptive cell transfer therapy |
|---|
| Anmerkungen: |
Date Completed 16.01.2024 Date Revised 27.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.bbcan.2023.189022 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364842725 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364842725 | ||
| 003 | DE-627 | ||
| 005 | 20240229170434.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.bbcan.2023.189022 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1310.xml |
| 035 | |a (DE-627)NLM364842725 | ||
| 035 | |a (NLM)37993001 | ||
| 035 | |a (PII)S0304-419X(23)00171-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhang, Sirui |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hurdle or thruster |b Glucose metabolism of T cells in anti-tumour immunity |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.01.2024 | ||
| 500 | |a Date Revised 27.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a Glucose metabolism is essential for the activation, differentiation and function of T cells and proper glucose metabolism is required to maintain effective T cell immunity. Dysregulation of glucose metabolism is a hallmark of cancer, and the tumour microenvironment (TME2) can create metabolic barriers in T cells that inhibit their anti-tumour immune function. Targeting glucose metabolism is a promising approach to improve the capacity of T cells in the TME. The efficacy of common immunotherapies, such as immune checkpoint inhibitors (ICIs3) and adoptive cell transfer (ACT4), can be limited by T-cell function, and the treatment itself can affect T-cell metabolism. Therefore, understanding the relationship between immunotherapy and T cell glucose metabolism helps to achieve more effective anti-tumour therapy. In this review, we provide an overview of T cell glucose metabolism and how T cell metabolic reprogramming in the TME regulates anti-tumour responses, briefly describe the metabolic patterns of T cells during ICI and ACT therapies, which suggest possible synergistic strategies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Adoptive cell transfer therapy | |
| 650 | 4 | |a Glucose metabolism | |
| 650 | 4 | |a Immune checkpoint | |
| 650 | 4 | |a Metabolic reprogramming | |
| 650 | 4 | |a T cell | |
| 650 | 4 | |a Tumour microenvironment | |
| 650 | 7 | |a Glucose |2 NLM | |
| 650 | 7 | |a IY9XDZ35W2 |2 NLM | |
| 700 | 1 | |a Zhang, Xiaozhen |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Hanshen |e verfasserin |4 aut | |
| 700 | 1 | |a Liang, Tingbo |e verfasserin |4 aut | |
| 700 | 1 | |a Bai, Xueli |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biochimica et biophysica acta. Reviews on cancer |d 1998 |g 1879(2024), 1 vom: 01. Jan., Seite 189022 |w (DE-627)NLM097444006 |x 1879-2561 |7 nnns |
| 773 | 1 | 8 | |g volume:1879 |g year:2024 |g number:1 |g day:01 |g month:01 |g pages:189022 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.bbcan.2023.189022 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 1879 |j 2024 |e 1 |b 01 |c 01 |h 189022 | ||